FDA Approved: METHYLIN — Supplemental Application (SHIONOGI INC.)

View source ↗

Summary

FDA approved a supplemental application for MethyLin (methylphenidate hydrochloride) submitted by Shionogi under NDA 021419.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Narcolepsy

Drugs mentioned

• METHYLIN (Methylphenidate hydrochloride)

Snippet

SUPPL AP for METHYLIN (METHYLPHENIDATE HYDROCHLORIDE)